Outlook Therapeutics slumps after US FDA declines to approve drug for eye condition

** Shares of Outlook Therapeutics OTLK.O slump 66.8% to 78 cents premarket

** U.S. FDA declines to approve co's drug for a type of eye condition called wet age-related macular degeneration (wet AMD) that causes blurred vision

** OTLK says the FDA's letter included only one deficiency - a lack of substantial evidence of effectiveness

** Up to last close, stock up 26% YTD